Abstract Background/Aims: Myocardial infarction (MI) is a leading cause of morbidity and mortality. Here, we sought to explore the potential role and underlying mechanism of miR-145 in MI. Methods: H9c2 cells were cultured under persistent hypoxia to simulate MI. The hypoxiainduced injury was assessed on the basis of cell viability, migration, invasion and apoptosis. The expression of miR-145 was evaluated by qRT-PCR and the influence of aberrantly expressed miR-145 on H9c2 cells under hypoxia was also estimated. Utilizing bioinformatics methods, the target genes of miR-145 were verified by luciferase reporter assay. Then, effects of abnormally expressed target gene on miR-145 silenced H9c2 cells were assessed. Finally, the phosphorylation levels of key kinases in the phosphatidylinositol-3-kinase (PI3K)/AKT and the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways were detected by Western blot analysis. Results: Hypoxia remarkably lowered viability, migration and invasion but promoted cell apoptosis. Meantime, the miR-145 level was up-regulated in H9c2 cells under hypoxia. Following experiments suggested that hypoxiainduced injury was exacerbated by miR-145 overexpression while was alleviated by miR-145 silence. Rac1 was predicted and further validated to be a target gene of miR-145. The influence of miR-145 silencing on H9c2 cells under hypoxia could be reversed by down-regulation of Rac1. Additionally, the phosphorylation levels of PI3K, AKT, MAPK and ERK were all elevated in miR-145 silenced cells and these alterations were reversed by down-regulation of Rac1. Conclusion: miR-145 silencing could protect H9c2 cells against hypoxia-induced injury by targeting Rac1, in which PI3K/AKT and MAPK/ERK pathways might be involved.
MicroRNA-145 Aggravates HypoxiaInduced Injury by Targeting Rac1 in H9c2 Cells

Introduction
Myocardial infarction (MI) is a leading cause of morbidity and mortality around the world [1, 2] . The World Health Organization (WHO) originally defined MI according to clinical symptoms of chest pain, electrocardiogram (ECG) abnormalities and enzymes [3] . On account of pathology, MI is defined as myocardial cell death induced by prolonged ischemia, presenting discomfort of chest, nausea, dyspnea, syncope and diaphoresis [4, 5] . Accumulating evidence has reported that MI is caused by sudden blockage in the coronary arteries, resulting in deficient supply for the heart muscle. Atherosclerosis, in which cholesterol and white blood cells accumulate in the wall of the artery, is commonly considered as a reason of MI [6] . Even though MI is considered as a minor event, it may cause sudden death or sever haemodynamic deterioration [7] . Thus, it is really urgent to explore effective therapeutic targets for treatment of MI.
MicroRNAs (miRNAs) are endogenous small noncoding RNA with a length of 19-25 nt [8] . miRNAs are reported to function through binding to 3'-untranslated region (3'UTR) of numerous target genes, resulting in degradation of mRNA or translation block [9, 10] . Mounting literatures have proved that miRNAs are involved in multiple diseases including MI [11] [12] [13] . A previous study has reported miRNA (miR)-99a alleviates heart remodeling and improves cardiac performance after MI [14] . Another study illustrated circulating miR-1 acts as a novel biomarker for MI [15] . Thus, deep investigations on the influence of miRNAs in MI might provide a novel avenue for clinical treatments.
The functional roles of miR-145 in cancer have been well studied. For example, miR-145 is proved to act as a tumor suppressor, along with significant inhibition of cell proliferation and motility by suppressing Rho Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) in hepatocellular carcinoma [16] . Conversely, miR-145 is suggested to facilitate proliferation and migration in endothelial progenitor cells [17] . As for MI, miR-145 is reported as a marker for estimation of infarct size during MI [18] . More recently, miR-145 is also proved to be a novel biomarker for prognosticating cardiac function as well as the risk of heart failure [19] . To our knowledge, the modulation of miR-145 in MI is far from sufficiently clear.
Considering the controversial roles of miR-145 in physiological process and the urgent need for exploring effective therapeutic target for MI, we focused on the functional roles of miR-145 in MI. Under hypoxia, the expression and role of miR-145 in H9c2 cells were systematically studied. Moreover, the possible target genes of miR-145 and the underlying mechanism of the modulation were also investigated.
Materials and Methods
Cell culture and treatments Immortalized H9c2 cells, derived from fetal rat heart, were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). H9c2 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM, Gbico, Grand Island, NY, USA) containing 10 % (v/v) fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin (all from Invitrogen, Carlsbad, CA, USA) at 37°C. Under normoxic condition, cells were incubated in a humidified incubator containing 95% air and 5% CO 2 . However, the hypoxic condition was realized by incubation in a hypoxic incubator containing 94% N 2 , 5% CO 2 and 1% O 2 . The hypoxia treatment was lasted for 6 hours. 
Quantitative reverse transcription PCR (qRT-PCR)
Total RNA was extracted from H9c2 cells using Trizol reagent (Life Technologies Corporation, Carlsbad, CA, USA) following the manufacturer's instructions. For estimation of miR-145 expression, the Taqman MicroRNA Reverse Transcription Kit and Taqman Universal Master Mix II (both from Applied Biosystems, Foster City, CA, USA) were used in turns for revers transcription and quantitative PCR, respectively. U6, RNU6B and RNU48 were acted as internal controls, and the relative expressions were expressed as the average levels normalized to these three factors. For estimation of Rac1 mRNA expression, MultiScribe™ Reverse Transcriptase (Applied Biosystems) was used to convert total RNA into cDNA in line with supplier's protocol. Then, Rac1 mRNA expression was assessed by quantitative PCR using Power SYBR™ Green Master Mix (Applied Biosystems) according to the manufacturer's instructions. GAPDH, RNU6B and RNU48 were used as the internal controls, and the relative expressions were expressed as the average levels normalized to these three factors. Primers used were synthesized by Sangon Biotech (Shanghai, China) and are listed in the Table 1 . The expression levels of miR-145 and Rac1 mRNA in H9c2 cells were calculated on the basis of the 2 -ΔΔCt method [20] .
Cell transfection miR-145 mimic and its control (mimic control), antisense oligonucleotide (ASO) targeting miR-145 (ASO-miR-145) and its control (ASO control), and small interfering RNA targeting Rac1 (si-Rac1) were synthesized by GenePharma Co. (Shanghai, China). Lipofectamine 3000 reagent (Invitrogen) was used for cell transfection following the manufacturer's protocol.
CCK-8 assay
The cell viability was estimated by a Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Gaithersburg, MD, USA). Briefly, cells with a density of 5 × 10 3 cells per well were seeded in a 96-well plate. After treatment, 10 μL of CCK-8 solution was added into each well, and the mixture was incubated for additional 1 h at 37°C with 5% CO 2 . The absorbance at 450 nm was measured using a Microplate Reader (Bio-Rad, Hercules, CA, USA).
Migration and invasion assays
Cell migration was determined by a modified Boyden chamber assay using 24-well Transwell (8 μm pore size; Costar, Corning, NY, USA) as described previously [21] . In brief, the lower chamber was filled with 600 μL complete culture medium, whereas the upper chamber was filled with 1 × 10 5 H9c2 cells suspended in 200 μL serum-free medium. Cells were incubated at 37°C for 24 h, and then were fixed with methanol. After careful remove of the non-traversed cells on the upper surface of the filter using a cotton swab, the traversed cells on the lower surface of the filter were stained with 0.1% crystal violet. Cell number was counted in five randomly selected fields by a blind investigator using a microscope (Olympus, Tokyo, Japan) at 200× magnification. Each experiment was run in triplicate. The process of cell invasion measurement was as the same as cell migration except that the insert was pre-coated with Matrigel (BD Bioscience, San Jose, CA, USA).
Apoptosis assay
The apoptotic cells were identified and quantified by flow cytometry analysis using an Annexin V-FITC/PI apoptosis detection kit (Beijing Biosea Biotechnology, Beijing, China) following the supplier's suggestions. In brief, the H9c2 cells with a density of 1 × 10 5 cells/well were seeded in a 6 well-plate. After treatment, cells were washed twice with ice-cold phosphate-buffered saline (PBS) and resuspended in binding buffer. The adherent and floating cells were combined and stained by 10 μL Annexin V-FITC and 5 μL propidium iodide (PI) in line with the manufacturer's protocol, followed by measurement with a flow cytometer (Beckman Coulter, Miami, FL, USA) to differentiate apoptotic cells (Annexin-V positive and PInegative) from necrotic cells (Annexin-V and PI-positive). Each experiment was performed in triplicate.
Luciferase reporter assay
Utilizing bioinformatics method, putative target genes of miR-145 were screened. Fragments containing the putative miR-145 binding site of the wild Rac1 3'UTR were sub-cloned into pmirGLO vector (Promega, Fitchburg, WI, USA) to generate luciferase reporter plasmid (Rac1-WT). After sequencing, Cellular Physiology and Biochemistry
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Directed Mutagenesis System (Invitrogen) was used to construct mutant Rac1-WT, which was referred to as Rac1-Mut. H9c2 cells were co-transfected with Rac1-WT (Rac1-Mut) and miR-145 mimic (mimic control) using Lipofectamine 3000 reagent (Invitrogen). Together, pRL-TK (Promega) containing renilla gene was also transfected into cells acting as internal control. After transfection, Dual-Luciferase Reporter Assay System (Promega) was utilized to estimate the luciferase activity following the manufacturer's information.
Western blot analysis
Total proteins were extracted from treated cells in line with a previously described method [22] . After quantification using the BCA™ Protein Assay Kit (Pierce, Appleton, WI, USA), equivalent proteins were loaded and separated by a Bio-Rad Bis-Tris Gel system according to the manufacturer's instructions. Then, proteins were transferred to polyvinylidene difluoride (PVDF) membranes and the membranes were blocked with nonfat milk. After rinsing, the membranes were incubated at 4°C overnight with antibodies against B cell lymphoma-2 (Bcl-2, ab196495), Bcl-2-associated X protein (Bax, ab182733), pro caspase-3 (ab44976), cleaved caspase-3 (ab49822), Rac1 (ab33186), phospho-phosphatidylinositol 3-kinase (p-PI3K, ab182651), GAPDH (ab181603), hypoxanthine-guanine phosphoribosyltransferase (HPRT, ab109021), tubulin (ab7291) (all from Abcam, Cambridge, UK), pro caspase-9 (9506), cleaved caspase-9 (9507), PI3K (4292), AKT (9272), phospho-AKT (p-AKT, 9271), mitogen-activated protein kinase (MAPK, 9212), phospho-MAPK (p-MAPK, 9211), extracellular signal-regulated kinase (ERK, 9102) or phospho-ERK (p-ERK, 9101) (all from Cell Signaling Technology, Beverly, MA, USA). After rinsing again, the membranes were incubated with secondary antibodies marked by horseradish peroxidase for 1 h at room temperature. Afterwards, the membranes carrying blots and antibodies were washed and transferred into the Bio-Rad ChemiDoc™ XRS system, followed by addition of 200 μL Immobilon Western Chemiluminescent HRP substrate (Millipore, Billerica, MA, USA). The signals were captured and the bands were analyzed using Image Lab™ software (Bio-Rad).
Statistical analysis
All experiments were repeated three times. The results are presented as the mean ± standard deviation (SD). Statistical analysis was performed using Graphpad Prism 5 software (GraphPad, San Diego, CA, USA). The P-values were calculated using the one-way analysis of variance (ANOVA) or unpaired two-tailed t-test. A P-value of < 0.05 was considered to indicate a statistically significant result.
Results
Hypoxia induces cell injury of H9c2 cells
To investigate the effects of hypoxia on H9c2 cells, cell viability, migration, invasion and apoptosis of H9c2 cells were evaluated under normoxic or anaerobic condition. Compared with the control group, in which cells were incubated under normoxic condition, hypoxia significantly reduced cell viability, migration and invasion (all P < 0.05, Fig. 1A-1C ) but promoted cell apoptosis (P < 0.001, Fig. 1D ). In addition, the results in Fig. 1E-1F showed expression of Bcl-2 was markedly decreased by hypoxia (P < 0.05), whereas expression of Bax was significantly enhanced by hypoxia (P < 0.01). Active caspase-3 and caspase-9 were expressed in the hypoxia group but not in the control group. Data suggested that hypoxia could induce H9c2 cell injury.
Hypoxia induces up-regulation of miR-145
The influence of hypoxia on miR-145 expression was further explored by qRT-PCR. In Fig. 2 , miR-145 was markedly up-regulated by hypoxia compared with cells cultured under normoxia (P < 0.05). Thus, we concluded that hypoxia could induce up-regulation of miR-145 in H9c2 cells.
miR-145 is aberrantly expressed in the transfected H9c2 cells
After cell transfection, miR-145 level in the miR-145 mimic group was significantly upregulated compared with that in the mimic control group (P < 0.01, Fig. 3 ). Conversely, ASO- 
miR-145 silence protects H9c2 cells from hypoxia-induced injury
After transfection with mimic control, miR-145 mimic, ASO control or ASO-miR-145, H9c2 cells were cultured under hypoxia, followed by assessments of cell viability, migration, invasion and apoptosis. Non-treated cells were acted as control. In Fig. 4A-4C , hypoxiainduced decreases of cell viability, migration and invasion were all alleviated by miR-145 knockdown compared with that in the ASO control groups (all P < 0.05). Conversely, these decreases induced by hypoxia were further reduced by miR-145 overexpression compared with that in the mimic control groups (all P < 0.05). The effects of aberrantly expressed miR-145 on cell apoptosis was just the opposite (Fig. 4D) . Meantime, the hypoxia-induced downregulation of Bcl-2 (P < 0.01) was further down-regulated by miR-145 overexpression (P < 0.05) but was reversed by miR-145 knockdown (P < 0.01; Fig. 4E-4F ). The influence of aberrantly expressed miR-145 on expression of Bax was opposite to Bcl-2 expression. The hypoxia-induced expressions of active caspase-3 and active caspase-9 were increased by miR-145 overexpression (P < 0.01 or P < 0.001) but were reduced by miR-145 silence (P < 0.001). All the data implied the hypoxia-induced injury in H9c2 cells was attenuated by miR-145 knockdown.
miR-145 negatively regulates expression of Rac1 and Rac1 is a target of miR-145
Through bioinformatics methods, Rac1 is predicted to be a target gene of miR-145. Results in Fig. 5A -5C manifested expressions of Rac1 at mRNA and protein levels were significantly down-regulated by miR-145 overexpression when compared to cells transfected 
miR-145 silence attenuates hypoxia-induced injury through up-regulating Rac1
To validate whether Rac1 was involved in the influence of miR-145 on hypoxia-induced injury, H9c2 cells were transfected with ASO control, ASO-miR-145 alone or accompanied with si-Rac1 and then cells were cultured under hypoxia. Non-treated cells were acted as control. Under hypoxic condition, the effects of miR-145 knockdown on cell viability, migration, invasion, apoptosis and expressions of apoptosis-associated proteins were all reversed by Rac1 knockdown compared with the ASO-miR-145 groups (P < 0.05, P < 0.01 or P < 0.001; Fig. 6A-6F ). Thus, we drew a conclusion that miR-145 silence could attenuate hypoxia-induced injury through up-regulating Rac1.
miR-145 silence activates the PI3K/AKT and MAPK/ERK pathways through up-regulating Rac1
To reveal the underlying mechanisms on the miR-145-associated modulations, the phosphorylated levels of key kinases in the PI3K/AKT and MAPK/ERK signaling pathways were evaluated by Western blot analysis. In Fig. 7A-7D , phosphorylated levels of PI3K, AKT, MAPK and ERK were all lowered by hypoxia (P < 0.01 or P < 0.001), along with down-Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry regulation of Rac1 (P < 0.05 or P < 0.01), compared with the control groups. Under hypoxic condition, phosphorylated levels of these four kinases were all enhanced by miR-145 inhibition (P < 0.01 or P < 0.001), along with up-regulation of Rac1 (P < 0.01). When the Rac1 was knocked down, the miR-145 silence-induced increases of p-PI3K, p-AKT, p-MAPK and p-ERK were all significantly reduced (P < 0.001). Taken together, we concluded that miR-145 silence could activate the PI3K/AKT and MAPK/ERK pathways through up-regulating Rac1 in H9c2 cells under hypoxia.
Discussion
Even though the treatments for MI have been developed, MI could cause acute death and long-term complications, for example, heart failure [23] . There is a growing interest on exploration of novel therapeutic targets for MI. In our study, we found cell viability, migration and invasion were all repressed by hypoxia but cell apoptosis was promoted. Meantime, the miR-145 was up-regulated under hypoxic condition. Then, we interestingly found the effects of hypoxia on H9c2 cells were aggravated by miR-145 overexpression but were reversed by miR-145 knockdown. Afterwards, miR-145 was proved to negatively regulate Rac1, which was further validated as a target gene of miR-145. Additionally, the effects of miR-145 knockdown on H9c2 cells could be abrogated by Rac1 silence. Western blot analysis revealed that miR-145 inhibition could reverse hypoxia-induced inactivation of the PI3K/AKT and MAPK/ERK pathways through up-regulating Rac1 expression.
Hypoxia is the important and original reason of MI. Cellular hypoxia causes large numbers of cellular events, resulting in loss of myocardium [24, 25] . Then, ventricular begins to be remodeled gradually, accompanied by fibrosis, chamber enlargement and heart failure [26] . Herein, we employed hypoxia to simulate the process of MI in H9c2 cells. Consistent with previous literatures [27, 28] , cell viability was inhibited but cell apoptosis was promoted in H9c2 cells under persistent hypoxia. Unlike the effects of hypoxia on cancer cells [29] , cell migration and invasion in H9c2 cells were both inhibited by hypoxia. In addition, hypoxia down-regulated Bcl-2 while up-regulated Bax. The decrease of Bcl-2/Bax can facilitate the activation of caspase-9 and thereby increase the activation of caspase-3, resulting in cleavage of proteins in the cytoskeleton, membranes and nucleus [30] . In our study, hypoxia activated caspase-9 and casapase-3, providing a rational explanation for the alterations of cell viability and apoptosis in H9c2 cells under hypoxia.
A previous literature proved that hypoxia markedly modifies the miRNA profile in the heart [31] . As miR-145 is reported as a biomarker for MI [32] , we explored the alteration of miR-145 in H9c2 cells under hypoxia. The results showed that miR-145 was up-regulated, suggesting the possible involvement of miR-145 in hypoxia-induced injury of H9c2 cells. Subsequently, miR-145 level in H9c2 cells was abnormally expressed, followed by assessments of cell viability, migration, invasion, apoptosis and expressions of apoptosisassociated proteins under hypoxia. The results in our study manifested that hypoxia-induced injury of H9c2 cells was notably increased by miR-145 overexpression while was alleviated by miR-145 repression, suggesting a potential therapeutic strategy related to miR-145 for MI.
In a bioinformatics analysis, 3'UTR of Rac1 was predicted to bind to miR-145. Rac1 is a GTPase that is involved in diverse physiological activities, including cell growth, migration and invasion [33] . Until now, large numbers of miRNAs are reported to act as tumor suppressors by targeting Rac1, including miR-142 and miR-146a [34, 35] . Previous studies also proved that Rac1 participates in various cardiovascular pathologies, for example, cardiomyocyte hypertrophy [36] . However, the specific association between miR-145 and Rac1 in H9c2 cells remains unclear. Therefore, we explored the alteration of Rac1 expression when miR-145 level changed. The results in our study suggested the fact that miR-145 negatively regulated Rac1 expression and could significantly reduce luciferase activity when co-transfected with Rac1-WT, demonstrating Rac1 was a target gene of miR-145. More evidences followed also Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry implied the effects of miR-145 inhibition on H9c2 cells under hypoxia could be reversed by down-regulation of Rac1, consolidating that Rac1 was a target gene of miR-145. Activated PI3K helps to anchor AKT to the plasma membrane, followed by phosphorylation of AKT. Activation of AKT is proved to participate in multiple cellular activities, including cell proliferation, apoptosis, migration and invasion [37] . More recently, the PI3K/AKT pathway is reported to protect myocardial cells from ischemic injury [38] . Likewise, the MAPK/ERK is implicated in cell survival and proliferation, and a previous literature also illustrated the MAPK/ERK pathway could protect myocardium from ischemic injury in vivo [39] . To reveal the underlying mechanism of the miR-145-associated modulation in H9c2 cells under hypoxia, the phosphorylation levels of key kinases in the PI3K/AKT and MAPK/ ERK pathways were investigated. The results in our study stated that these two pathways were both inactivated by hypoxia, whereas the alterations were reversed by miR-145 silence, along with up-regulation of Rac1. Besides, the effects of miR-145 silence on phosphorylation levels of these kinases were abrogated by the silence of Rac1 in H9c2 cells under hypoxia.
Taken together, we interestingly found miR-145 was up-regulated in H9c2 cells under persistent hypoxia and miR-145 silence could protect H9c2 cells from hypoxia-induced injury. Moreover, miR-145 silence was proved to function through modulation of Rac1, along with activations of the PI3K/AKT and MAPK/ERK signaling pathways. The results in our study provide novel perspectives for clinical diagnose and treatment of MI. To further verify whether miR-145 silence functions through activations of these two pathways, more investigations are still needed.
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